Gilead reported a strong quarter in product sales but its stock fell after investors reacted to guidance and mixed early uptake of Yeztugo, a recently launched long‑acting HIV prevention product. Management posted quarterly wins—Biktarvy and Descovy outperformed forecasts—but Yeztugo’s fourth‑quarter sales fell below some analysts’ ‘‘whisper’’ numbers, prompting a market pullback. Gilead reiterated fiscal guidance and described policy headwinds related to prior pricing agreements as manageable, but the quarter highlighted how investor expectations for new product launches can amplify stock volatility even when core franchises deliver.